Pharmacological Management of Postural Hypotension

First-Line Pharmacological Therapy

The American Diabetes Association recommends midodrine as the first-line pharmacological treatment for postural hypotension, with a dosage of 10 mg up to three times daily, and the last dose at least 3-4 hours before bedtime 1, 2
Midodrine is FDA-approved for orthostatic hypotension treatment, with a mechanism of action as a peripheral selective α1-adrenergic agonist causing arteriolar and venous constriction 1

The European Society of Cardiology recommends fludrocortisone as a mineralocorticoid that increases sodium retention and expands fluid volume, with a dosage of 0.1-0.3 mg once daily 3
Clonidine/Guanfacine may be useful for patients with high supine blood pressure, and should be taken at bedtime 2, 4, 5

The American Heart Association recommends fluid and salt intake, targeting 2-3 L of fluids and 10g of salt daily, as well as physical countermeasures such as leg crossing, squatting, and muscle tensing during position changes 1, 3
Compression garments, such as abdominal binders and/or compression stockings, can reduce venous pooling 1, 2, 3

For diabetic patients, the American Diabetes Association recommends considering underlying autonomic neuropathy as a cause of postural hypotension, and optimizing glucose control to prevent progression of autonomic dysfunction 1, 2, 4
For elderly patients, the European Society of Cardiology recommends starting with lower doses and titrating more gradually, and monitoring closely for supine hypertension 1, 3, 6
For heart failure patients, the European Society of Cardiology recommends prioritizing SGLT2 inhibitors and MRAs as they have minimal impact on blood pressure, and spacing out medications to reduce synergistic hypotensive effects 7